Both in healthy people and in patients with non-insulin dependent (type 2) diabetes mellitus, glibenclamide lowers blood glucose concentration by stimulating insulin release from the betacells of the pancreas. This effect operates in interaction with glucose (improvement in the responsiveness of beta-cells to the physiological glucose stimulus). Glibenclamide is also reported as having extrapancreatic effects: it reduces hepatic glucose production and enhances insulin binding and insulin sensitivity in peripheral tissues.
Add additional product information here.
Add your shipping and returns information here.